Comparative Pharmacology
Head-to-head clinical analysis: DEPO ESTRADIOL versus FEMTRACE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEPO ESTRADIOL versus FEMTRACE.
DEPO-ESTRADIOL vs FEMTRACE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Estradiol is an estrogen hormone that binds to estrogen receptors (ERα and ERβ) in target tissues, modulating gene transcription and exerting effects such as proliferation of endometrial tissue, regulation of gonadotropin secretion (negative feedback on FSH and LH), and maintenance of secondary sexual characteristics.
Estrogen receptor agonist; binds to estrogen receptors, modulating gene transcription and cellular proliferation in target tissues.
1 to 5 mg intramuscularly every 3 to 4 weeks for estrogen replacement therapy.
1 to 2 mg orally once daily; for testosterone replacement in adult males, 2 to 4 mg orally once daily.
None Documented
None Documented
The terminal elimination half-life of estradiol after intramuscular injection of Depo-Estradiol is approximately 5-9 days, reflecting slow release from the depot and prolonged systemic exposure.
Terminal elimination half-life is approximately 12-14 hours, supporting once-daily dosing in clinical use.
Estradiol is extensively metabolized in the liver, with conjugated metabolites (glucuronides and sulfates) primarily excreted in urine (about 90%) and feces (about 10%). Less than 5% is excreted unchanged.
Primarily renal; ~40% as unchanged drug and glucuronide conjugates. Biliary/fecal elimination is minor (~10-15%).
Category D/X
Category C
Estrogen
Estrogen